Alexander L Schwarzman

Title: Alexander L Schwarzman: Innovator in Amyloid Beta-Protein Detection

Introduction

Alexander L Schwarzman is a notable inventor based in St. James, NY (US). He has made significant contributions to the field of biomedical research, particularly in the detection of soluble amyloid beta-protein. His work is crucial in understanding and potentially preventing conditions associated with amyloid aggregation in the brain.

Latest Patents

Schwarzman holds a patent for "Methods for the detection of soluble amyloid .beta.-protein (.beta.AP)." This invention focuses on methods and compositions aimed at preventing the aggregation of amyloid beta-protein, which is linked to the deposition of amyloid in the brain. The patent describes amyloid beta-protein-binding compounds, such as transthyretin, which form complexes with beta-AP to inhibit amyloid formation. Additionally, it identifies the serine 6 mutation in the TTR gene as a predictive marker for individuals at risk of developing beta-AP associated amyloidosis. He has 1 patent to his name.

Career Highlights

Schwarzman is affiliated with The State University of New York, where he continues to engage in innovative research. His work has implications for understanding neurodegenerative diseases and developing therapeutic strategies.

Collaborations

He has collaborated with notable colleagues, including Moises Eisenberg-Grunberg and Dmitry Y Goldgaber, contributing to advancements in his field.

Conclusion

Alexander L Schwarzman is a key figure in the research of amyloid beta-protein detection, with a focus on preventing its aggregation. His contributions are vital for advancing our understanding of related diseases and potential treatments.